GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment.
GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.
GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...
GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.
GSK respiratory/immunology research and development global head Kaivan Khavandi stated: “Working with Relation enables us to ...
As part of the deal, GSK will pay Relation $45 million in upfront payments, which includes an equity investment of $15 million.
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...
The Muna alliance was announced shortly after GSK signed a deal with Rgenta Therapeutics to develop RNA-directed ...
GSK PLC GSK shares shed 2.40% to £13.41 Wednesday, on what proved to be an all-around positive trading session for the stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback